Publication | Closed Access

Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial

VaccinationVaccine SafetyOpen-label Phase 2TransplantationVaccine DevelopmentVaccine ResearchImmunologyTherapeutic VaccineVirologyMedicineCell TransplantationCytomegalovirus Dna Vaccine